Therapeutic Drugs for Central Nervous System (CNS) Disorders: Technologies and Global Markets

• Publication date: September 2010

THIS REPORT CONTAINS Discussion of such disease areas as psychotherapeutics, seizure, ADHD, insomnia, migraines, and Parkinson’s Analysis of global market trends, with data for 2009, estimates for 2010, and projections of compound annual growth rates (CAGRs) through 2015 A focus on drug classes, including selective serotonin reuptake inhibitors (SSRIs); selective norepinephrine reuptake inhibitors (SNRIs); monoamine oxidas...

THIS REPORT CONTAINS

Discussion of such disease areas as psychotherapeutics, seizure, ADHD, insomnia, migraines, and Parkinson’s
Analysis of global market trends, with data for 2009, estimates for 2010, and projections of compound annual growth rates (CAGRs) through 2015
A focus on drug classes, including selective serotonin reuptake inhibitors (SSRIs); selective norepinephrine reuptake inhibitors (SNRIs); monoamine oxidase inhibitors (MAOIs); tricyclic antidepressants (TCA); inhibition of acetylcholinesterase (AChEI) and NMDA receptors; dopamine agonists; catechol O-methyl transferase inhibitors (COMT inhibitors); and dopaminergics
A breakdown of markets by geography, including emerging markets
Comprehensive company profiles.

STUDY GOALS AND OBJECTIVES

This study provides a comprehensive analysis of central nervous system therapies on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease sub–segments to overall industry trends, in order to quantify and qualify the market for therapeutic drug products in the central nervous system sector. Individual products are forecast on a global basis, as are overall segments. Forecasts and trends are developed from a cross reference of data points, gleaned from proprietary industry sources, company publications, industry benchmarking, and other divergent data sources to arrive at a cogent and coordinated forecast.

REASONS FOR DOING THE STUDY

For companies with an effective strategy, market opportunity awaits. Importantly, the ability to develop an effective strategy begins with opportunity and ends with effective execution in order to capture profit. 

The central nervous system therapeutic market is perhaps the most important of any drug sector. Market growth has been spurred by the introduction of differentiated therapies due to novel mechanism of action, such as serotonin and norepinephrine reuptake inhibitors (SNRIs). In contrast to technical innovation, patent expiry is producing a headwind that will cause the overall market to remain essentially flat through the forecast period.

This report analyzes emerging markets by disease segment. Continued growth is expected in emerging geographies, driven by the growing middle class in countries such as India, China, Brazil and Russia. 

This report seeks to address the critically important topics of analyzing a changing market dynamic, emerging players and technologies, strategies for accessing emerging markets, and specific disease segments and geographies in order to allocate resources and make effective decisions. 

SCOPE OF REPORT

Current and projected product forecasts during the period 2010 through 2015 are discussed. As well as, new products approved in 2009 and 2010 by the Federal Drug Administration (FDA), and those products expected to be approved within the forecast period. 2010 is an estimated figure, except where actual results have been reported, due to the release timing of the report. For large markets segments such as Psychiatry, Depression, Alzheimer’s, and others, detailed disease investigation is pursued. For example, the mixing trend of increased use of selective serotonin reuptake inhibitors (SSRIs) as a first line therapy as compared to SNRIs is analyzed. For each core segment within the overall market, leading products are analyzed for their differentiation by mechanism of action. 

The report includes analysis of leading and emerging competitors in the current worldwide central nervous system market. Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development are analyzed to define their specific product strategies. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products and technologies are influencing the current standard of care. Detailed profiles of current market leaders are discussed, as well as companies with innovative products poised to advance within the forecast period.

Market figures are based on revenues at the manufacturers’ level and are projected at 2010–dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded indications for existing products, and projected changes in the prevalence, diagnosis, and scripting rates for certain diseases. 

Included in this report are forecasts by product, product category, and by company from 2009 through 2015. The study is arranged to offer an overview of the central nervous system market accompanied by product, company, geography, and mechanism of action with forecasts broken down and covered by geographic region or country. Virtually the entire globe is covered to include prevalence data, for each disease subsegment.   

Excluded from this report are over the counter (OTC) medications, a detailed generics analysis, and other consumables that do not require a physician prescription. 

Sales figures are reported in current U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.
All market share data presented is on a global basis, unless specifically noted. 

INTENDED AUDIENCE

This report is an invaluable tool for business planners, acquisition specialists, licensing strategists, product managers, market research analysts, investors, investor consultants and anyone interested in the central nervous system market, its products, its industry participants and its future.

The importance of identifying overall market trends, product opportunities, emerging geographies, merger and acquisition opportunities and insights that provide guidance for sales growth or defensive moves cannot be overstated for a variety of constituents, including: 

Established companies in the industry shall benefit from the contents, including corporate strategy, sales and marketing, business development, and R&D. 
Emerging biotechnology players in the segment must understand specific opportunities for out–licensing, originating from the elements of differentiation of their therapeutic drug as compared to leading, competitive, and emerging therapies. As well, market forecasts can support investment, provided a thorough and detailed substantiation is provided for the market forecast, as is found in this study. 
Investment firms evaluating candidates for venture capital or hedged investments will gain insights as to the opportunity and risks that are being encountered in the industry, in a product and company specific analysis. 
Equity analysts are provided detailed forecasts for the next 5 years, substantiated by quantitative analysis that can support further analysis to product and company forecasts over the short and long term.

METHODOLOGY AND INFORMATION SOURCES

Both primary and secondary research methodologies were used in preparing this report. Detailed interviews were conducted in–person and via telephone with industry participants, equity and industry analysts, leading medical physicians and other experts in the field. 

Information to prepare this report was obtained from participating and emerging companies in the central nervous system market including: American Medical Association, The American Parkinson Disease Association, The National Multiple Sclerosis Society, the National Institute of Mental Health, and The American Journal of Psychiatry, Depression and Anxiety, American Parkinson Disease Association, and others; the World Health Organization and other government agencies; literature searches; annual reports; 10Ks, and others. Population estimates are based on those reported by the international database of the U.S. Census Bureau.

Current and historical revenue figures for individual products have been sourced from company disclosures that exist in the public domain or from government sources.

Global Therapy Industry

Chapter- 1: INTRODUCTION -- Complimentary

STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THE STUDY 1
SCOPE OF REPORT 2
INTENDED AUDIENCE 3
METHODOLOGY AND INFORMATION SOURCES 3
BCC ONLINE SERVICES 4
DISCLAIMER 5

Chapter-2: EXECUTIVE SUMMARY

SUMMARY TABLE GLOBAL CENTRAL NERVOUS SYSTEM FORECAST BY DISEASE CLASS, THROUGH 2015 ($ MILLIONS) 6
SUMMARY FIGURE GLOBAL CENTRAL NERVOUS SYSTEM FORECAST BY DISEASE CLASS, 2008-2015 ($ MILLIONS) 7
EXECUTIVE SUMMARY (CONTINUED) 8

Chapter-3: OVERVIEW

CURRENT STATE OF CENTRAL NERVOUS SYSTEM DISEASE 9
ESTABLISHED DRUG SEGMENTS 10
PSYCHIATRY 10
DEPRESSION 10
MULTIPLE SCLEROSIS / PARKINSON’S 10
EPILEPSY/CONVULSION 11
ALZHEIMER’S 11
ATTENTION DEFICIT HYPERACTIVITY DISORDER/NARCOLEPSY 11
MIGRAINE 11
OTHER 12
KEY RECENT EVENTS IN THE CENTRAL NERVOUS SYSTEM MARKET 12
2009 FDA PEDIATRIC ADVISORY COMMITTEE ON PRESCRIPTION OF ANTIPSYCHOTICS 12
GROWTH SEEN VIA PURSUIT OF ADDITIONAL INDICATIONS VERSUS NCE APPROVALS 13
ALZHEIMER’S DRUGS IN JAPAN OPEN UP LARGE OPPORTUNITIES, DRIVEN BY DEMOGRAPHICS 13
SUMMARY PIPELINE OF DRUGS IN DEVELOPMENT 13
TABLE 1 RECENTLY APPROVED AND PIPELINE FORECAST, 2009-2015 ($ MILLIONS) 14

Chapter-4: INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS

INDUSTRY STRUCTURE 15
TABLE 2 CENTRAL NERVOUS SYSTEM MARKET SEGMENTS: SIZE, GROWTH, SHARE ($ MILLIONS) 16
MARKET CONCENTRATION AND PRICE SENSITIVITY 17
TABLE 3 COMPANY BY DISEASE CLASS, 2010 REVENUE ($ MILLIONS) 18
TABLE 3 (CONTINUED) 19
MARKET TRENDS 19
Overall Market Flat: Higher Mix of Generics Offset by Higher Volume 19
Significant Impact of Patient Advocacy Groups in CNS Disease 20
Growth Seen via Pursuit of Additional Indications versus NCE Approvals 20
Improving Performance in Depression Treatments 20
Alzheimer’s Therapy Continues to Receive Large and Important Investment 20
TABLE 4   PATENT EXPIRATION OF CENTRAL NERVOUS SYSTEM DRUGS, 2010 AND 2015 ($ MILLIONS) 21
TABLE 5 COMPANY BY DISEASE CLASS, 2015 REVENUE ($ MILLIONS) 22
TABLE 6 MARKET SHARE BY LEADING CENTRAL NERVOUS SYSTEM PLAYERS, 2010 ($ MILLIONS/%) 23
TABLE 7 LARGEST REVENUE GENERATING THERAPIES IN THE CENTRAL NERVOUS SYSTEM DISEASE ($ MILLIONS) 24

Chapter-5: MARKETS BY DISEASE

SUMMARY OF MARKET DYNAMICS 25
TABLE 8 GLOBAL CENTRAL NERVOUS SYSTEM FORECAST BY DISEASE CLASS THROUGH 2015 ($ MILLIONS) 26
PSYCHIATRY 26
MARKET DYNAMICS 26
TREATMENT AND MANAGEMENT 27
TABLE 9   CURRENT GLOBAL PSYCHIATRY MARKET, THROUGH 2010 ($ MILLIONS) 27
TABLE 9 (CONTINUED) 28
Seroquel 28
Zyprexa 29
Abilify 29
Geodon/Zeldox 30
Risperdal 31
TABLE 10 GLOBAL PSYCHIATRY MARKET, THROUGH 2015 ($ MILLIONS) 32
TABLE 11 FORECAST EPIDEMIOLOGY: PSYCHIATRY 32
DEPRESSION 33
MARKET DYNAMICS 33
TREATMENT AND MANAGEMENT 33
TABLE 12 CURRENT GLOBAL DEPRESSION MARKET, THROUGH 2010 ($ MILLIONS) 33
Lexapro 34
Effexor 34
Cymbalta 35
GENERIC DRUG TRENDS: DEPRESSION 35
TABLE 13   GLOBAL DEPRESSION MARKET, THROUGH 2015 ($ MILLIONS) 36
TABLE 14 FORECAST EPIDEMIOLOGY: DEPRESSION 36
MULTIPLE SCLEROSIS AND PARKINSON’S 36
MARKET DYNAMICS 36
TABLE 15 CURRENT GLOBAL MS AND PARKINSON’S MARKET, THROUGH 2010 ($ MILLIONS) 37
TREATMENT AND MANAGEMENT 37
Requip 37
GENERIC DRUG TRENDS: PARKINSON’S 38
TABLE 16   GLOBAL MS AND PARKINSON’S MARKET, THROUGH 2015 ($ MILLIONS) 38
TABLE 17 FORECAST EPIDEMIOLOGY: MS/PARKINSONS, THROUGH 2015 39
EPILEPSY/CONVULSIONS 39
MARKET DYNAMICS 39
TABLE 18   CURRENT GLOBAL EPILEPSY MARKET, THROUGH 2010 ($ MILLIONS) 39
TABLE 18 (CONTINUED) 40
TREATMENT AND MANAGEMENT 40
Topamax 40
Lyrica 40
Lamictal 41
GENERIC DRUG TRENDS: EPILEPSY/CONVULSIONS 41
TABLE 19 GLOBAL EPILEPSY MARKET, THROUGH 2015 ($ MILLIONS) 42
ALZHEIMER’S 42
MARKET DYNAMICS 42
TABLE 20 CURRENT GLOBAL ALZHEIMER’S MARKET, THROUGH 2010 ($ MILLIONS) 43
TREATMENT AND MANAGEMENT 44
Aricept 44
Exelon 44
Namenda 45
TABLE 21 GLOBAL ALZHEIMER’S MARKET, THROUGH 2015 ($ MILLIONS) 45
TABLE 21 (CONTINUED) 46
GENERIC DRUG TRENDS: ALZHEIMER’S 46
ADHD AND NARCOLEPSY 46
MARKET DYNAMICS 46
TABLE 22 CURRENT GLOBAL ADHD / NARCOLEPSY MARKET, THROUGH 2010 ($ MILLIONS) 47
TREATMENT AND MANAGEMENT 47
Concerta 47
Provigil 48
Vyvanse 48
Adderall 49
Strattera 49
TABLE 23 GLOBAL ADHD/NARCOLEPSY MARKET, THROUGH 2015 ($ MILLIONS) 50
GENERIC DRUG TRENDS: ADHD/NARCOLEPSY 50
MIGRAINE AND OTHER CNS DISEASE 50
MARKET DYNAMICS 50
TABLE 24 CURRENT GLOBAL MIGRAINE DISEASE MARKET, THROUGH 2010 ($ MILLIONS) 51
TABLE 25 CURRENT GLOBAL OTHER CNS DISEASE MARKET, THROUGH 2010 ($ MILLIONS) 51
TABLE 25 (CONTINUED) 52
TREATMENT AND MANAGEMENT 52
Ambien 52
Lunesta 52
TABLE 26   GLOBAL MIGRAINE MARKET, THROUGH 2015 ($ MILLIONS) 53
TABLE 27 GLOBAL OTHER CENTRAL NERVOUS SYSTEM MARKET THROUGH 2015 ($ MILLIONS) 54

Chapter-6: MARKETS BY GEOGRAPHY

SUMMARY 55
TABLE 28 CURRENT MARKET SIZE BY GEOGRAPHY, THROUGH 2010 ($ MILLIONS) 55
METHODOLOGY 55
TABLE 29 MARKET FORECAST BY GEOGRAPHY, THROUGH 2015 ($ MILLIONS) 56
UNITED STATES 56
TABLE 30   PREVALENCE OF EPIDEMIOLOGY IN THE U.S.: PSYCHIATRY, THROUGH 2015 57
TABLE 31 PEVALENCE OF EPIDEMIOLOGY IN THE U.S.: DEPRESSION, THROUGH 2015 57
TABLE 32 PREVALENCE OF EPIDEMIOLOGY IN THE U.S.: STROKE, THROUGH 2015 57
WESTERN EUROPE 57
TABLE 33 PREVALENCE OF EPIDEMIOLOGY IN WESTERN EUROPE: PSYCHIATRY, THROUGH 2015 58
TABLE 34 PREVALENCE OF EPIDEMIOLOGY IN WESTERN EUROPE: DEPRESSION, THROUGH 2015 59
TABLE 35 PREVALENCE OF EPIDEMIOLOGY IN WESTERN EUROPE: STROKE, THROUGH 2015 59
JAPAN 59
TABLE 36 PREVALENCE OF EPIDEMIOLOGY IN JAPAN: PSYCHIATRY, THROUGH 2015 60
TABLE 37 PREVALENCE OF EPIDEMIOLOGY IN JAPAN: DEPRESSION, THROUGH 2015 60
EMERGING MARKETS 60
STRATEGIES TO ACCESS EMERGING MARKETS 60
EMERGING MARKETS FORECAST 61
BRAZIL 62
Market Overview 62
Regulatory Considerations 62
Patent Considerations 62
TABLE 38 PREVALENCE OF EPIDEMIOLOGY IN BRAZIL: PSYCHIATRY, THROUGH 2015 63
TABLE 39 PREVALENCE OF EPIDEMIOLOGY IN BRAZIL: DEPRESSION, THROUGH 2015 63
TABLE 40 PREVALENCE OF EPIDEMIOLOGY IN BRAZIL: STROKE, THROUGH 2015 64
CHINA 64
Market Overview 64
Regulatory Considerations 64
Patent Considerations 65
TABLE 41 PREVALENCE OF EPIDEMIOLOGY IN CHINA: PSYCHIATRY, THROUGH 2015 66
TABLE 42 PREVALENCE OF EPIDEMIOLOGY IN CHINA: DEPRESSION, THROUGH 2015 66
TABLE 43 PREVALNCE OF EPIDEMIOLOGY IN CHINA: STROKE, THROUGH 2015 66
INDIA 67
Market Overview 67
Regulatory Considerations 67
Patent Considerations 67
TABLE 44 PREVALENCE OF EPIDEMIOLOGY IN INDIA: PSYCHIATRY, THROUGH 2015 68
TABLE 45 PREVALENCE OF EPIDEMIOLOGY IN INDIA: DEPRESSION, THROUGH 2015 68
TABLE 46 PREVALENCE OF EPIDEMIOLOGY IN INDIA: STROKE, THROUGH 2015 68
RUSSIA 69
Market Overview 69
Regulatory Considerations 69
Patent Considerations 69
TABLE 47 PEVALENCE OF EPIDEMIOLOGY IN RUSSIA: PSYCHIATRY, THROUGH 2015 70
TABLE 48 PREVALENCE OF EPIDEMIOLOGY IN RUSSIA: DEPRESSION, THROUGH 2015 70
TABLE 49 PREVALENCE OF EPIDEMIOLOGY IN RUSSIA: STROKE, THROUGH 2015 70
SOUTH AMERICA 70
TABLE 50 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AMERICA: PSYCHIATRY, THROUGH 2015 71
TABLE 51 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AMERICA: DEPRESSION, THROUGH 2015 71
TABLE 52 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AMERICA: STROKE, THROUGH 2015 71
CARIBBEAN 71
TABLE 53 PREVALENCE OF EPIDEMIOLOGY IN THE CARIBBEAN: PSYCHIATRY, THROUGH 2015 72
TABLE 54 PREVALENCE OF EPIDEMIOLOGY IN THE CARIBBEAN: DEPRESSION, THROUGH 2015 72
TABLE 55 PREVALENCE OF EPIDEMIOLOGY IN THE CARIBBEAN: STROKE, THROUGH 2015 72
NORTHERN EUROPE 73
TABLE 56 PREVALENCE OF EPIDEMIOLOGY IN NORTHERN EUROPE: PSYCHIATRY, THROUGH 2015 73
TABLE 57 PREVALENCE OF EPIDEMIOLOGY IN NORTHERN EUROPE: DEPRESSION, THROUGH 2015 73
TABLE 58 PREVALENCE OF EPIDEMIOLOGY IN NORTHERN EUROPE: STROKE, THROUGH 2015 73
CENTRAL AND EASTERN EUROPE 74
TABLE 59 PREVALENCE OF EPIDEMIOLOGY IN CENTRAL AND EASTERN EUROPE: PSYCHIATRY, THROUGH 2015 74
TABLE 60 PREVALENCE OF EPIDEMIOLOGY IN CENTRAL AND EASTERN EUROPE: DEPRESSION, THROUGH 2015 74
TABLE 61 PREVALENCE OF EPIDEMIOLOGY IN CENTRAL AND EASTERN EUROPE: STROKE, THROUGH 2015 74
AUSTRALIA 75
TABLE 62 PREVALENCE OF EPIDEMIOLOGY IN AUSTRALIA: PSYCHIATRY, THROUGH 2015 75
TABLE 63 PREVALENCE OF EPIDEMIOLOGY IN AUSTRALIA: DEPRESSION, THROUGH 2015 75
TABLE 64 PREVALENCE OF EPIDEMIOLOGY IN AUSTRALIA: STROKE, THROUGH 2015 75
ASIA–OTHER 76
TABLE 65 PREVALENCE OF EPIDEMIOLOGY IN ASIA - OTHER: PSYCHIATRY, THROUGH 2015 76
TABLE 66 PREVALENCE OF EPIDEMIOLOGY IN ASIA - OTHER: DEPRESSION, THROUGH 2015 76
TABLE 67 PREVALENCE OF EPIDEMIOLOGY IN ASIA - OTHER: STROKE, THROUGH 2015 76
MIDDLE EAST 77
TABLE 68 PREVALENCE OF EPIDEMIOLOGY IN THE MIDDLE EAST: PSYCHIATRY, THROUGH 2015 77
TABLE 69 PREVALENCE OF EPIDEMIOLOGY IN THE MIDDLE EAST: DEPRESSION, THROUGH 2015 77
TABLE 70 PREVALENCE OF EPIDEMIOLOGY IN THE MIDDLE EAST: STROKE, THROUGH 2015 77
SOUTHERN AFRICA 78
TABLE 71 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AFRICA: PSYCHIATRY, THROUGH 2015 78
TABLE 72 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AFRICA: DEPRESSION, THROUGH 2015 78
TABLE 73 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AFRICA: STROKE, THROUGH 2015 78
AFRICAN REGIONS EXCLUDED FROM EPIDEMIOLOGY FORECAST 79

Chapter-7: PIPELINE ANALYSIS

TABLE 74 APPROVED PRODUCT FORECAST, 2009-2015 ($ MILLIONS) 80
MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT 80
KEY TRENDS IN RESEARCH AND DEVELOPMENT 80
SNRIs Improve the Baseline Performance of Leading Depression Therapies 80
New Products Provide Larger Opportunities Compared to Product Extensions 81
Combination Products Yield Greater Therapeutic Response 81
Alzheimer’s Therapy Continues to Receive Large and Important Investment 82
KEY PRODUCTS UNDER MAJOR CNS DISORDERS 82
Schizophrenia 82
Depression 83
Alzheimer’s 83
Parkinson’s Disease 84
Epilepsy 84
Insomnia 84
Attention Deficit Hyperactivity Disorder 85
Other Indications 85
2009 APPROVALS IN CENTRAL NERVOUS SYSTEM THERAPY 85
PHASE III AND PENDING APPROVAL COMPOUNDS 85
Bapineuzumab (AAB–001)—Elan/Wyeth/Pfizer 85
TABLE 75   BAPINEUZUMAB (AAB–001)—ELAN/WYETH/PFIZER 85
Bapineuzumab (Continued) 86
Telcagepant (MK–0974)—Merck 87
TABLE 76 TELCAGEPANT (MK–0974)—MERCK 87
Telcagepant … (Continued) 88
Solanezumab (LY2062430)—Eli Lilly 89
TABLE 77 SOLANEZUMAB (LY2062430)—ELI LILLY 89
Semagacestat (LY450139)—Eli Lilly 90
TABLE 78 SEMAGACESTAT (LY450139)—ELI LILLY 90
Vilazodone—Clinical Data 91
TABLE 79 VILAZODONE—CLINICAL DATA 91
RECENTLY APPROVED/MARKETED DRUGS 92
Stedesa/Zebinix (eslicarbazepine acetate)—Dainippon Sumitomo (formerly Sepracor) 92
TABLE 80 STEDESA/ZEBINIX (ESLICARBAZEPINE ACETATE)—DAINIPPON SUMITOMO (FORMERLY SEPRACOR) 92
Intuniv (guanfacine)—Shire 93
TABLE 81 INTUNIV (GUANFACINE)—SHIRE 93
Treximet (Sumatriptan and Naproxen)—GSK/Pozen 94
TABLE 82 TREXIMET (SUMATRIPTAN AND NAPROXEN)—GSK/POZEN 94
Treximet …(Continued) 95
Pristiq (desvenlafaxine)—Pfizer/Wyeth 96
TABLE 83 PRISTIQ (DESVENLAFAXINE)—PFIZER/WYETH 96
Vimpat (lacosamide)—UCB/Schwarz Pharma 97
TABLE 84 VIMPAT (LACOSAMIDE)—UCB/SCHWARZ PHARMA 97
TABLE 85 DEVELOPMENTAL PRODUCT FORECAST, 2009-2015 ($ MILLIONS) 98

Chapter-8: COMPANY PROFILES

SUMMARY 99
TABLE 86 COMPANY REVENUE AND MARKET SHARE ANALYSIS, THROUGH 2010 ($ MILLIONS) 99
TABLE 86 (CONTINUED) 100
TABLE 87 MARKET FORECAST BY COMPANY, THROUGH 2015 ($ MILLIONS) 100
TABLE 87 (CONTINUED) 101
COMPANIES 101
ABBOTT LABORATORIES 101
Business Overview 101
Therapeutic Areas 102
TABLE 88 ABBOTT LABORATORIES’ LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 102
Corporate Strategy 102
ALLERGAN, INC. 102
Business Overview 102
Therapeutic Areas 103
TABLE 89 ALLERGAN’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 103
Corporate Strategy 103
Business Overview 103
Therapeutic Areas 104
TABLE 90 ASTELLAS’ LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 104
Corporate Strategy 104
ASTRAZENECA 104
Business Overview 104
Therapeutic Areas 105
TABLE 91 ASTRAZENECA’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 105
Corporate Strategy 105
BAYER AG 106
Business Overview 106
Therapeutic Areas 106
TABLE 92 BAYER HEALTHCARE’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 107
Corporate Strategy 107
BIOGEN IDEC (FUMAPHARM AG) 107
Business Overview 107
Therapeutic Areas 107
TABLE 93 BIOGEN’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 107
Corporate Strategy 108
ELI LILLY & CO. 108
Business Overview 108
Therapeutic Areas 108
TABLE 94 ELI LILLY’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 108
Corporate Strategy 109
FOREST LABORATORIES, INC. 109
Business Overview 109
Therapeutic Areas 110
TABLE 95 FOREST LABORATORIES’ LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 110
Corporate Strategy 110
GLAXOSMITHKLINE (GSK) 110
Business Overview 110
Therapeutic Areas 111
TABLE 96 GLAXOSMITHKLINE’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 111
Corporate Strategy 111
JOHNSON & JOHNSON 112
Business Overview 112
Therapeutic Areas 112
TABLE 97 JOHNSON & JOHNSON’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 112
Corporate Strategy 112
MERCK & CO., INC. 113
Business Overview 113
Therapeutic Areas 113
TABLE 98 LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 114
Corporate Strategy 114
Business Overview 114
Therapeutic Areas 114
TABLE 99 NOVARTIS’ LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 115
Corporate Strategy 115
PFIZER, INC. 115
Business Overview 115
Therapeutic Areas 116
TABLE 100 PFIZER’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 116
Corporate Strategy 116
SANOFI–AVENTIS 117
Business Overview 117
Therapeutic Areas 117
TABLE 101 SANOFI–AVENTIS’ LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 117
Corporate Strategy 117
SHIRE PHARMACEUTICALS GROUP, PLC 118
Business Overview 118
Therapeutic Areas 118
TABLE 102 SHIRE’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 118
Corporate Strategy 118
Business Overview 119
Therapeutic Areas 119
TABLE 103 TAKEDA’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 119
Corporate Strategy 119
TEVA PHARMACEUTICAL INDUSTRIES LTD 120
Business Overview 120
Therapeutic Areas 120
TABLE 104 TEVA’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 120
Corporate Strategy 121
WATSON PHARMACEUTICALS, INC. 121
Business Overview 121
Therapeutic Areas 121
TABLE 105 WATSON’S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 121
Corporate Strategy 121